Home The Action MC Substitutes/Other Reinhard Schinzel (DE)

Sat,19Apr2014

Prof. Dr. Reinhard Schinzel

vasopharm GmbH
Friedrich-Bergius-Ring 15
D-97076 Würzburg / Germany
Fon: +49 (0)931-359099-115
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Research Interests
vasopharm has developed VAS203, a cofactor-derived Nitric Oxide Synthase Inhibitor particularly for the treatment of the consequences of closed head injuries. The inhibitor is currently tested in clinical studies. Furthermore, vasopharm is interested in new approaches to measure NO bioavailability in blood, in particular in platelets using the phosphorylation state of a specific platelet protein (VASP).


Selected Recent Publications

  • Geiger J, Brandmann T, Hubertus K, Tjahjadi B, Schinzel R, Walter U. A protein phosphorylation-based assay for screening and monitoring of drugs modulating cyclic nucleotide pathways. Anal Biochem. 2010 Dec 15;407(2):261-9.
  • Terpolilli NA, Zweckberger K, Trabold R, Schilling L, Schinzel R, Tegtmeier F, Plesnila N. The novel nitric oxide synthase inhibitor 4-amino-tetrahydro-L-biopterine prevents brain edema formation and intracranial hypertension following traumatic brain injury in mice. J Neurotrauma. 2009 Nov;26(11):1963-75.
  • Geiger J, Teichmann L, Grossmann R, Aktas B, Steigerwald U, Walter U, Schinzel R. Monitoring of clopidogrel action: comparison of methods. Clin Chem. 2005 Jun;51(6):957-65.

ESF

COST

POLICY STATEMENT: Biomedicine and Molecular Biosciences Action BM1005 is funded by COST, through its implementing agent the European Science Foundation.